237 related articles for article (PubMed ID: 33675192)
21. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer.
Lin YH; Wu CH; Fu HC; Chen YJ; Chen YY; Ou YC; Lin H
Cancer Biomark; 2020; 28(3):285-292. PubMed ID: 32390605
[TBL] [Abstract][Full Text] [Related]
22. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A
BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772
[TBL] [Abstract][Full Text] [Related]
23. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
24. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Boerner T; Filippova OT; Chi AJ; Iasonos A; Zhou QC; Long Roche K; Zivanovic O; Park BJ; Huang J; Jones DR; Abu-Rustum NR; Gardner G; Sonoda Y; Chi DS
Gynecol Oncol; 2020 Oct; 159(1):66-71. PubMed ID: 32792282
[TBL] [Abstract][Full Text] [Related]
25. The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery.
Yang SP; Chen JX; Xu JY; Lei J; Wu SG; Zhou J
Cancer Med; 2022 Jul; 11(14):2836-2845. PubMed ID: 35274489
[TBL] [Abstract][Full Text] [Related]
26. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
27. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Morrison J; Haldar K; Kehoe S; Lawrie TA
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005343. PubMed ID: 22895947
[TBL] [Abstract][Full Text] [Related]
29. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.
Qin L; Huang H; Chen M; Liang Y; Wang H
J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567
[TBL] [Abstract][Full Text] [Related]
30. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
[TBL] [Abstract][Full Text] [Related]
31. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
Onda T; Satoh T; Ogawa G; Saito T; Kasamatsu T; Nakanishi T; Mizutani T; Takehara K; Okamoto A; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Kanao H; Watanabe Y; Yamamoto K; Yaegashi N; Kamura T; Yoshikawa H;
Eur J Cancer; 2020 May; 130():114-125. PubMed ID: 32179446
[TBL] [Abstract][Full Text] [Related]
32. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
33. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
[TBL] [Abstract][Full Text] [Related]
34. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
[TBL] [Abstract][Full Text] [Related]
36. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
[TBL] [Abstract][Full Text] [Related]
37. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
38. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.
Lee J; Curtin JP; Muggia FM; Pothuri B; Boyd LR; Blank SV
Cancer Chemother Pharmacol; 2018 Jul; 82(1):55-63. PubMed ID: 29704010
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.
Nagao S; Tamura J; Shibutani T; Miwa M; Kato T; Shikama A; Takei Y; Kamiya N; Inoue N; Nakamura K; Inoue A; Yamamoto K; Fujiwara K; Suzuki M
Int J Clin Oncol; 2023 Jun; 28(6):804-815. PubMed ID: 37140771
[TBL] [Abstract][Full Text] [Related]
40. The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
Rawert FL; Luengas-Würzinger V; Claßen-Gräfin von Spee S; Baransi S; Schuler E; Carrizo K; Dizdar A; Mallmann P; Lampe B
Arch Gynecol Obstet; 2022 Nov; 306(5):1665-1672. PubMed ID: 35357582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
